Goldman Sachs keeps $47 target on Novo Nordisk stock
Goldman Sachs has reaffirmed its Neutral rating and $47 price target on Novo Nordisk stock after meeting management at a healthcare conference.
The bank had lifted that target to $47 from $41 on June 3, so the conference note effectively cemented its stance.
Novo Nordisk shares had hit a 52-week low near $37 earlier this year, down from a high above $90, after its next-generation obesity drug missed a key trial goal in February.